Search research articles
Contact Us
Filters
Showing results (161-170 of 187) with videos related to
Page
of 19
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 7, 2011
Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis
E Sbardella, V Tomassini, M L Stromillo, et al.
Neurology
|
September 8, 2010
Safety and efficacy of natalizumab in children with multiple sclerosis
A Ghezzi, C Pozzilli, L M E Grimaldi, et al.
AJNR. American Journal of Neuroradiology
|
September 17, 2021
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis
G Pontillo, S Tommasin, R Cuocolo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 17, 2011
Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis
B Goretti, E Portaccio, A Ghezzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 27, 2005
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study
A Ghezzi, M P Amato, M Capobianco, et al.
Neurology
|
November 14, 2008
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
D R Altmann, B Jasperse, F Barkhof, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
July 3, 2007
Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results
A Ghezzi, M P Amato, M Capobianco, et al.
Neurology
|
January 5, 2002
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS
P A Brex, P D Molyneux, P Smiddy, et al.
European Journal of Neurology
|
March 3, 2011
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A Novotna, J Mares, S Ratcliffe, et al.
Journal of Neurology
|
December 6, 2018
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
E D'Amico, A Zanghì, M Sciandra, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 187) with videos related to
Sort By:
Page
of 19
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 7, 2011
Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis
E Sbardella, V Tomassini, M L Stromillo, et al.
Neurology
|
September 8, 2010
Safety and efficacy of natalizumab in children with multiple sclerosis
A Ghezzi, C Pozzilli, L M E Grimaldi, et al.
AJNR. American Journal of Neuroradiology
|
September 17, 2021
A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis
G Pontillo, S Tommasin, R Cuocolo, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
August 17, 2011
Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis
B Goretti, E Portaccio, A Ghezzi, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
July 27, 2005
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study
A Ghezzi, M P Amato, M Capobianco, et al.
Neurology
|
November 14, 2008
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis
D R Altmann, B Jasperse, F Barkhof, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
July 3, 2007
Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results
A Ghezzi, M P Amato, M Capobianco, et al.
Neurology
|
January 5, 2002
The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS
P A Brex, P D Molyneux, P Smiddy, et al.
European Journal of Neurology
|
March 3, 2011
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A Novotna, J Mares, S Ratcliffe, et al.
Journal of Neurology
|
December 6, 2018
Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience
E D'Amico, A Zanghì, M Sciandra, et al.
Page
of 19